Skip to main content
RNXT
NASDAQ Life Sciences

RenovoRx报告首个全年1.1M美元RenovoCath收入，确认强劲的现金储备和试验进展

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
8
Price
$1.07
Mkt Cap
$39.215M
52W Low
$0.701
52W High
$1.45
Market data snapshot near publication time

summarizeSummary

RenovoRx报告了其2025年全年财务结果，强调了其RenovoCath设备在商业化首个全年中的1.1百万美元收入。该公司还提供了业务更新，确认了强劲的现金储备为1300万美元，其中包括最近关闭的1000万美元私募。另外，第三阶段TIGeR-PaC临床试验将于2026年中完成招募，截至目前已有104名患者随机分配，建立在最近超过100名患者的里程碑之上。这一全面更新提供了新的财务指标和积极的运营进展，表明RenovoCath的初步市场采纳和坚实的财务跑道。投资者将关注持续的商业化增长和TIGeR-PaC试验的及时完成。

在该公告发布时，RNXT的交易价格为$1.07，交易所为NASDAQ，所属行业为Life Sciences，市值约为$3921.5万。 52周交易区间为$0.70至$1.45。 这则新闻被评估为积极市场情绪，重要性评分为8/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed RNXT - Latest Insights

RNXT
Apr 27, 2026, 5:20 PM EDT
Filing Type: 424B3
Importance Score:
8
RenovoRx Registers Resale of 15.9 Million Shares from Recent Private Placement, Creating Significant Market Overhang
Sentiment: Negative
View Wiseek Article
RNXT
Apr 16, 2026, 5:10 PM EDT
Filing Type: S-3
Importance Score:
8
RenovoRx Registers Over $20 Million in Shares and Warrants for Resale by Private Placement Investors
Sentiment: Negative
View Wiseek Article
RNXT
Apr 08, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
RenovoCath Device Secures First Japanese Patent Allowance, Bolstering Global IP and Asia Expansion
Sentiment: Positive
View Wiseek Article
RNXT
Mar 30, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
RenovoRx Reports $1.1M RenovoCath Revenue in First Full Year, Confirms Strong Cash Position & Trial Progress
Sentiment: Positive
View Wiseek Article
RNXT
Mar 27, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
7
RenovoRx Appoints Dr. Ramtin Agah as Executive Chairman with $450K Base Salary and Bonus Eligibility
Sentiment: Positive
View Wiseek Article
RNXT
Mar 26, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
RenovoRx's TIGeR-PaC Phase III Trial Surpasses 100 Patients, Nears Enrollment Completion
Sentiment: Positive
View Wiseek Article
RNXT
Mar 24, 2026, 9:16 PM EDT
Filing Type: 4
Importance Score:
7
RenovoRx CEO Invests $27,702 in Company's Recently Closed Private Placement
Sentiment: Positive
View Wiseek Article
RNXT
Mar 24, 2026, 9:15 PM EDT
Filing Type: 4
Importance Score:
8
CFO Mark Voll Invests $110,808 in RenovoRx Through Private Placement, Acquiring Stock and Warrants
Sentiment: Positive
View Wiseek Article
RNXT
Mar 23, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
RenovoRx Secures $10M Private Placement to Fund Commercialization and Phase III Trial
Sentiment: Positive
View Wiseek Article
RNXT
Mar 18, 2026, 8:35 AM EDT
Source: GlobeNewswire
Importance Score:
8
RenovoRx Secures $10M Private Placement, Issuing ~10.6M Shares and Warrants
Sentiment: Neutral
View Wiseek Article